Global Antiviral Drugs for Influenza Market Growth 2025-2031
Description
The global Antiviral Drugs for Influenza market size is predicted to grow from US$ 99 million in 2025 to US$ 139 million in 2031; it is expected to grow at a CAGR of 5.9% from 2025 to 2031.
Antiviral drugs for influenza are medications specifically designed to inhibit the replication of influenza viruses within the body. These drugs help reduce the severity and duration of flu symptoms, lower the risk of complications, and, in some cases, prevent infection. Antiviral drugs for influenza are classified into different categories based on their mechanisms of action, including neuraminidase inhibitors (e.g., oseltamivir, zanamivir, peramivir), polymerase inhibitors (e.g., baloxavir marboxil), and M2 proton channel inhibitors (e.g., amantadine, rimantadine, though these are rarely used due to resistance). They are most effective when taken within 48 hours of symptom onset and are typically available by prescription.
United States market for Antiviral Drugs for Influenza is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Antiviral Drugs for Influenza is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Antiviral Drugs for Influenza is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Antiviral Drugs for Influenza players cover BioCryst Pharmaceuticals, AdvaCare Pharma, Roche, GlaxoSmithKline, Morningside Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Antiviral Drugs for Influenza Industry Forecast” looks at past sales and reviews total world Antiviral Drugs for Influenza sales in 2024, providing a comprehensive analysis by region and market sector of projected Antiviral Drugs for Influenza sales for 2025 through 2031. With Antiviral Drugs for Influenza sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antiviral Drugs for Influenza industry.
This Insight Report provides a comprehensive analysis of the global Antiviral Drugs for Influenza landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antiviral Drugs for Influenza portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antiviral Drugs for Influenza market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antiviral Drugs for Influenza and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antiviral Drugs for Influenza.
This report presents a comprehensive overview, market shares, and growth opportunities of Antiviral Drugs for Influenza market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Neuraminidase Inhibitors
Polymerase Inhibitors
Segmentation by Application:
Over-the-counter (OTC)
Prescription (Rx)
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
BioCryst Pharmaceuticals
AdvaCare Pharma
Roche
GlaxoSmithKline
Morningside Pharmaceuticals
Avexima
Teva Pharmaceuticals
Daiichi Sankyo
Shionogi
Wockhardt
Key Questions Addressed in this Report
What is the 10-year outlook for the global Antiviral Drugs for Influenza market?
What factors are driving Antiviral Drugs for Influenza market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antiviral Drugs for Influenza market opportunities vary by end market size?
How does Antiviral Drugs for Influenza break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Antiviral drugs for influenza are medications specifically designed to inhibit the replication of influenza viruses within the body. These drugs help reduce the severity and duration of flu symptoms, lower the risk of complications, and, in some cases, prevent infection. Antiviral drugs for influenza are classified into different categories based on their mechanisms of action, including neuraminidase inhibitors (e.g., oseltamivir, zanamivir, peramivir), polymerase inhibitors (e.g., baloxavir marboxil), and M2 proton channel inhibitors (e.g., amantadine, rimantadine, though these are rarely used due to resistance). They are most effective when taken within 48 hours of symptom onset and are typically available by prescription.
United States market for Antiviral Drugs for Influenza is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Antiviral Drugs for Influenza is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Antiviral Drugs for Influenza is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Antiviral Drugs for Influenza players cover BioCryst Pharmaceuticals, AdvaCare Pharma, Roche, GlaxoSmithKline, Morningside Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Antiviral Drugs for Influenza Industry Forecast” looks at past sales and reviews total world Antiviral Drugs for Influenza sales in 2024, providing a comprehensive analysis by region and market sector of projected Antiviral Drugs for Influenza sales for 2025 through 2031. With Antiviral Drugs for Influenza sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antiviral Drugs for Influenza industry.
This Insight Report provides a comprehensive analysis of the global Antiviral Drugs for Influenza landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antiviral Drugs for Influenza portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antiviral Drugs for Influenza market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antiviral Drugs for Influenza and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antiviral Drugs for Influenza.
This report presents a comprehensive overview, market shares, and growth opportunities of Antiviral Drugs for Influenza market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Neuraminidase Inhibitors
Polymerase Inhibitors
Segmentation by Application:
Over-the-counter (OTC)
Prescription (Rx)
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
BioCryst Pharmaceuticals
AdvaCare Pharma
Roche
GlaxoSmithKline
Morningside Pharmaceuticals
Avexima
Teva Pharmaceuticals
Daiichi Sankyo
Shionogi
Wockhardt
Key Questions Addressed in this Report
What is the 10-year outlook for the global Antiviral Drugs for Influenza market?
What factors are driving Antiviral Drugs for Influenza market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antiviral Drugs for Influenza market opportunities vary by end market size?
How does Antiviral Drugs for Influenza break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
100 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Antiviral Drugs for Influenza by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Antiviral Drugs for Influenza by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
